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Abstract 
Background: Recent anti-malarial resistance monitoring in Angola has shown efficacy of artemether–lumefantrine 
(AL) in certain sites approaching the key 90% lower limit of efficacy recommended for artemisinin-based combination 
therapy. In addition, a controversial case of malaria unresponsive to artemisinins was reported in a patient infected in 
Lunda Sul Province in 2013.
Methods: During January–June 2015, investigators monitored the clinical and parasitological response of children 
with uncomplicated Plasmodium falciparum infection treated with AL, artesunate–amodiaquine (ASAQ), or dihy-
droartemisinin–piperaquine (DP). The study comprised two treatment arms in each of three provinces: Benguela (AL, 
ASAQ), Zaire (AL, DP), and Lunda Sul (ASAQ, DP). Samples from treatment failures were analysed for molecular markers 
of resistance for artemisinin (K13) and lumefantrine (pfmdr1).
Results: A total of 467 children reached a study endpoint. Fifty-four treatment failures were observed: four early treat-
ment failures, 40 re-infections and ten recrudescences. Excluding re-infections, the 28-day microsatellite-corrected 
efficacy was 96.3% (95% CI 91–100) for AL in Benguela, 99.9% (95–100) for ASAQ in Benguela, 88.1% (81–95) for AL in 
Zaire, and 100% for ASAQ in Lunda Sul. For DP, the 42-day corrected efficacy was 98.8% (96–100) in Zaire and 100% in 
Lunda Sul. All treatment failures were wild type for K13, but all AL treatment failures had pfmdr1 haplotypes associated 
with decreased lumefantrine susceptibility.
Conclusions: No evidence was found to corroborate the specific allegation of artemisinin resistance in Lunda Sul. 
The efficacy below 90% of AL in Zaire matches findings from 2013 from the same site. Further monitoring, particularly 
including measurement of lumefantrine blood levels, is recommended.
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Background
Ensuring that current first- and second-line anti-malari-
als remain efficacious is a key component of the interna-
tional effort to reduce malaria morbidity and mortality. 
Following World Health Organization (WHO) guidelines 
[1], Angolan national treatment policy recommends one 
of three artemisinin-based combination therapy (ACT) 
for the treatment of uncomplicated malaria: artemether–
lumefantrine (AL), artesunate–amodiaquine (ASAQ), or 
dihydroartemisinin–piperaquine (DP).
In recent years, strong evidence has accumulated that 
malaria parasites resistant to artemisinins have emerged 
and are spreading in certain parts of Southeast Asia [2, 3]. 
Monitoring and tracking these parasites has been facili-
tated by identification of mutations in the K13 propel-
ler gene that serve as molecular markers for artemisinin 
resistance [4].
Currently there is no evidence that artemisinin-resist-
ant parasites have appeared in sub-Saharan Africa, where 
the majority of global malaria morbidity and mortal-
ity is concentrated [5, 6]. No parasites with K13 muta-
tions associated with artemisinin resistance have been 
detected [6], and ACT efficacies have remained generally 
high [7–10]. However, past experience with the spread of 
chloroquine and sulfadoxine-pyrimethamine resistance 
stresses the importance of continued vigilance [11].
Angola, malaria endemic in its entirety, has occu-
pied a prominent place in recent anti-malarial resist-
ance monitoring in Africa [12]. Its large population of 
Asian immigrants and possible risk of importation of 
artemisinin-resistant parasites from that region drew 
attention following the publication of a controversial 
dispatch describing a case of apparent artemisinin treat-
ment failure in a Vietnamese immigrant who had lived 
in Lunda Sul Province [13–15]. Moreover, recent routine 
efficacy monitoring in Angola has shown some evidence 
of decreased lumefantrine susceptibility at certain sites. 
Therapeutic efficacy monitoring conducted in 2011–2013 
in the capital city Luanda reported an uncorrected effi-
cacy of AL of 91% in all ages, falling to 76% in a small sub-
set of participants under 5 years of age [16]. Therapeutic 
efficacy monitoring in 2013 in children in Zaire and Uíge 
Provinces showed high corrected efficacy of DP in both 
provinces, high AL corrected efficacy in Uíge Province, 
but a corrected efficacy below 90% in Zaire Province [17]. 
No K13 mutations were found in either the 2011–2013 
Luanda study or the 2013 Zaire/Uíge study, but pfmdr1 
genotypes previously associated with decreased lumefan-
trine susceptibility were reported in both studies.
Here, the results of the 2015 round of biennial thera-
peutic efficacy monitoring in Angola are presented from 
three provinces selected based on past efficacy results: 
Benguela, Zaire and Lunda Sul.
Methods
Study design
Data were collected as part of a six-arm clinical outcomes 
trial following the standard WHO in vivo therapeutic effi-
cacy protocol [18]. In each of three provinces, the efficacy 
of two of Angola’s three first-line ACT was measured: AL 
and DP in the mesoendemic-stable northern province of 
Zaire, AL and ASAQ in the mesoendemic-stable central 
coastal province of Benguela, and DP and ASAQ in the 
hyperendemic eastern province of Lunda Sul (Fig. 1). In 
each provincial capital, two public health facilities were 
selected as sentinel sites for patient enrolment. In each 
province, each anti-malarial regimen was tested consecu-
tively; there was no randomization of participants, and 
the study was not designed to compare efficacies of the 
three ACT.
Study population and enrolment
Children with symptomatic, uncomplicated Plasmo-
dium falciparum infection presenting to the sentinel 
health facilities and meeting standard inclusion criteria 
[18] were invited to participate in the trial. To account 
for differences in transmission intensity, the target age 
range was 6 months to 5 years (59 months) in Zaire and 
Lunda Sul, and 6 months to 12  years (143  months) in 
Benguela. Similarly, the acceptable initial parasite den-
sity was 2000–200,000 parasites/µL in Zaire and Lunda 
Sul and 1000–100,000 parasites/µL in Benguela. In addi-
tion to parasite density, haemoglobin was measured dur-
ing enrolment using HemoCue® 201 and 301 devices (AB 
Leo Diagnostics, Helsinborg, Sweden), with children hav-
ing haemoglobin >5 g/dL eligible for enrolment.
The target sample enrolment was 100 children per arm, 
providing enough power to estimate efficacy with 95% 
confidence limits of ±5% assuming an expected efficacy 
of 95% and a maximum loss to follow-up and exclusion 
rate of 27%.
Study procedures
Study participants were administered one of three anti-
malarials: AL (Coartem®; Novartis, Basel, Switzerland), 
ASAQ (Winthrop; Sanofi Aventis, Paris, France), and DP 
(Duo-cotecxin®; Holley-Cotec, Beijing, China). Study 
participants in the AL arm in Benguela received the 
regular formulation of Coartem, whereas those in the 
AL arm in Zaire received the dispersible formulation. 
AL was procured by The President’s Malaria Initiative 
and provided by the Angolan National Malaria Control 
Programme, and the ASAQ and DP were procured and 
provided by WHO. All medications passed lot-quality 
testing, performed in laboratories in the USA (AL), the 
Netherlands (DP) and South Africa (ASAQ), prior to 
the study. The participants were treated according to 
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manufacturers’ weight-based dosing recommendations. 
All three doses of ASAQ and DP were directly observed 
in the study health facilities. For AL, the morning doses 
were directly observed at the study health facilities, while 
the evening doses were given by participants’ guardians. 
To ensure appropriate administration of evening doses, 
guardians were counselled at the health facility and 
reminded in the evening by telephone. Guardians were 
also instructed to bring back empty blister packs the fol-
lowing day. Study participants not correctly completing 
the medication were withdrawn from the study.
Study participants were followed up daily for the first 
three days after initiation of treatment, and then weekly 
thereafter for a total of 28  days (AL and ASAQ arms) 
or 42  days (DP arms). At each follow-up visit, clinical 
response to treatment was monitored through a stand-
ardized history and physical examination and parasito-
logical response was assessed through preparation and 
examination of thick blood films (with the exception of 
day 1). Guardians were asked about any adverse events 
experienced by the study participants. Blood slides were 
prepared and read by two dedicated study laboratory 
technicians following standard procedures [18], and a 
sub-set of slides was read by expert microscopists from 
the Angolan National Malaria Control Programme dur-
ing supervisory visits and following study end. Dried 
blood spots were collected at enrolment and at all weekly 
follow-up visits. Additional blood spots were also col-
lected on day 3 in Zaire and Benguela. Follow-up was 
suspended for all study participants developing any 
danger signs and/or meeting criteria for treatment fail-
ure. Treatment failures were treated with intravenous 
quinine. An electronic database containing clinical and 
parasitological data was updated daily using double data 
entry.
Molecular analysis
Dried blood spots were transported to CDC laboratories 
in Atlanta. DNA was extracted using a QIAamp Blood 
DNA kit (Qiagen, Hilden, Germany) from day 0 and day-
of-failure samples for all treatment failures and day-0 
samples from 50 randomly selected participants with 
adequate clinical and parasitological response (ACPR).
For all treatment failure samples and the randomly 
selected treatment successes, the lengths of six microsat-
ellites [19] were measured: TA1, Polyα, PfPK2, C2M34, 
C3M69, and 2490. A previously described protocol for 
cycling [20] was modified for this study. Primer pairs with 
annealing temperature in the 50–60 °C range were designed 
and cycling conditions were optimized according to melting 
temperature for each primer pair. The sizes of the amplified 
products were assayed by capillary electrophoresis on an 
Applied Biosystems 3130xl sequencer (Applied Biosystems, 
Foster City, CA, USA). Microsatellite fragment analysis was 
performed using the Geneious Pro R8 microsatellite plug-in 
(Biomatters, San Francisco, CA, USA).
Regions in the P. falciparum K13, P. falciparum 
multidrug-resistance gene 1 (pfmdr1), and P. falcipa-
rum cytochrome b (pfcytb) genes were amplified and 
sequenced for day 0 and day of failure for all treat-
ment failures. The P. falciparum K13 propeller domain 
was amplified using a P. falciparum-specific protocol 
described previously [21]. Two regions of pfmdr1, cover-
ing codons 86–184 and 1034–1246, were amplified using 
a previously described protocol [22]. The pfcytb gene was 
amplified using the following primers: forward primer, 
5′ CTATTAATTTAGTTAAAGCACAC 3′ and reverse 
primer, 5′ ACAGAATAATCTCTAGCACCA 3′. 1 µL 
of genomic DNA was amplified using 0.5  µM of each 
primer, 0.2 mM dNTP, 2 mM MgCl2 and 1 U High Fidel-
ity Taq (New England Biolabs, Ipswich, MA, USA). For 
the primary reaction, the following cycling parameters 
were used: 2  min at 98  °C, 35 cycles of 98  °C for 10  s, 
46 °C for 30 s, 68 °C for 2:30 min, and final extension for 
10  min at 68  °C. Amplified PCR products were visual-
ized on a 2% agarose gel after electrophoresis. Sequenc-
ing of PCR products was performed using an ABI 3730 
sequencer (Applied Biosystems, Foster City, CA, USA).
Sanger sequences were analysed using Geneious R8 
software (Biomatters, San Francisco, CA, USA) to iden-
tify specific single-nucleotide polymorphism combina-
tions. Single-nucleotide polymorphisms were only called 
if both the forward and reverse strands had the mutation.
Fig. 1 Location of sentinel sites for therapeutic efficacy monitoring 
in Angola, 2015. AL artemether–lumefantrine, ASAQ artesunate–amo-
diaquine, DP dihydroartemisinin–piperaquine
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Statistical analysis
Study participants not meeting any exclusion criteria 
were classified as one of three possible study endpoints. 
Study participants showing signs of severe disease while 
parasitaemic in the first 3 days following treatment, hav-
ing a parasite density on day 2 that exceeded day 0 para-
site density, clearing less than 75% of day 0 parasites on 
day 3, or still febrile (≥37.5 °C axillary) and parasitaemic 
on day 3 were classified as early treatment failures (ETFs). 
Study participants that were febrile and parasitaemic 
after day 3 or parasitaemic regardless of body tempera-
ture after day 6 were classified as late treatment failures 
(LTFs). Participants not meeting these criteria with a 
negative slide on the last day of follow-up were classified 
as having an ACPR.
Kaplan–Meier estimates of the survival curve for each 
arm were calculated and plotted. Uncorrected efficacy 
was calculated as the proportion ACPR (per-protocol 
method), as well as the Kaplan–Meier estimate of the 
survival function at day 28 and/or 42. Microsatellite data 
for LTFs were analysed using a previously published sta-
tistical algorithm which assigns each LTF a posterior 
probability of recrudescence [23]. LTFs with a posterior 
probability of recrudescence >0.5 were classified as likely 
recrudescences; all others were classified as re-infec-
tions. The point estimates and 95% confidence intervals 
of the PCR-corrected efficacies were calculated by sam-
pling from the posterior distribution of classifications to 
account for the uncertainty of the correction [23]. Sta-
tistical analysis was performed using R version 3.0.1 (R 
Foundation for Statistical Computing, Vienna, Austria).
Ethical considerations
Parents or guardians of all study participants provided 
written informed consent prior to enrolment and were 
reimbursed for transport costs for clinic visits. The activ-
ity was classified as non-research by human subjects 
research boards at CDC and the Angolan Ministry of 
Health and was approved by the WHO Ethical Research 
Committee.
Results
A total of 1804 children were screened, of which 586 
(32%) were enrolled (Table 1). Five of the six arms reached 
the 100 participant target; enrolment in the ASAQ arm 
in Lunda Sul was stopped at 78 children due to a dimin-
ishing rate of patient eligibility following the start of the 
dry season. Loss to follow-up rates ranged from 7% in the 
AL arm in Zaire to 20% in the ASAQ arm in Benguela, 
which experienced severe floods during the study period 
(Table 2). A total of 46 study participants were excluded 
including: 21 participants who failed to complete treat-
ment, seven who developed a concomitant disease in the 
absence of parasitaemia, 14 who did not meet inclusion 
criteria but were erroneously enrolled, two with neces-
sary information not recorded on the form, one with 
Plasmodium vivax infection during follow-up, and one 
participant in the DP arm in Lunda Sul that developed 
severe malaria and died fewer than 24 h after enrolment. 
The minimal sample size of 73 study participants reach-
ing a study endpoint was achieved in all arms except for 
the ASAQ arm in Lunda Sul, where only 56 participants 
finished 28-day follow-up. Participant characteristics at 
baseline reflected the different inclusion criteria in each 
site (Table 1).
All medications were generally well tolerated. Vom-
iting following administration of the drug occurred in 
3.9% (7/179) of participants taking ASAQ, 7.3% (15/205) 
of participants taking AL, and 8.4% (17/202) of partici-
pants taking DP. One participant in the DP arm in Zaire 
experienced seizures on day 12 of follow-up, was negative 
for malaria by microscopy, and was excluded. No other 
adverse events were reported.
Clearance of parasites in all six arms was rapid, with 
clearance rates in each arm ranging from 94 to 100% on 
day 2, increasing to 99 to 100% on day 3 (Table 3). Four 
ETFs were reported. Three of the ETFs occurred in the 
AL arm in Zaire; in all three cases, the clinical status of 
the child worsened on day 1, and the child’s haemoglobin 
was measured to have fallen below 5 g/dL. Haemoglobin 
at enrolment in these study participants ranged from 6.2 
to 7.8 g/dL.
The Kaplan–Meier survival curves were markedly dif-
ferent for the six arms, with the Benguela ASAQ and 
both Lunda Sul arms showing maintained high efficacy 
over time, in contrast to the Benguela AL and both Zaire 
arms showing declining efficacy during follow-up (see 
Additional file  1: Figure S1). Overall, the uncorrected 
28-day efficacy using the Kaplan–Meier estimate of the 
survival curve was 90.3% (95% CI 84–97%) for the ASAQ 
arm in Benguela, 89.6% (83–96%) for the AL arm in Ben-
guela, 76.0% (68–85%) for the AL arm in Zaire, 95.5% 
(91–100%) for the DP arm in Zaire, 100% (94–100%) for 
the DP arm in Lunda Sul, and 100% for the ASAQ arm 
in Lunda Sul (Table  4). The uncorrected 42-day effi-
cacy of DP was 82.5% (75–91%) in Zaire and 100% (94–
100%) in Lunda Sul. The efficacies using the proportion 
ACPR indicator were not significantly different from the 
Kaplan–Meier estimate.
Of the 50 LTFs, 40 were reclassified as likely re-infec-
tions and ten as likely recrudescences. Due to high allelic 
diversity, there was little uncertainty around the classifi-
cation, with 44 of 50 (88%) LTFs having a probability of 
recrudescence either  >0.9 or  <0.1, signifying high con-
fidence (see Additional file 2: Table S1). The majority of 
recrudescences were observed in the AL arm in Zaire. 
Page 5 of 10Plucinski et al. Malar J  (2017) 16:62 
The corrected 28-day Kaplan–Meier efficacy estimates 
were 99.9% (95–100%) for the ASAQ arm in Benguela, 
96.3% (91–100%) for the AL arm in Benguela, 88.1% (81–
95%) for the AL arm in Zaire, 98.8% (96–100%) for the 
DP arm in Zaire, 100% for the DP arm in Lunda Sul, and 
100% for the ASAQ arm in Lunda Sul (Table 4). For DP, 
the corrected 42-day efficacies were 98.8% (96–100%) in 
Zaire and 100% in Lunda Sul.
All treatment failures were wild type for K13 and cytb 
(Table 5). The pfmdr1 gene, however, showed more diver-
sity, in particular in the polymorphic 86, 184 and 1246 
codons. Of the five observed pfmdr1 haplotypes, NYD 
(86N, 184Y, 1246D) and NFD (86N, 184F, 1246D) were 
the most common haplotypes, found in 61 (59%) and 33 
(32%) of tested samples, respectively. In the AL arms, the 
recrudescent and incident re-infections were all either 
NYD (61%, 17/28) or NFD (39%, 11/28).
Discussion
These therapeutic efficacy monitoring results from the 
three provinces demonstrate that the artemisinin compo-
nents of the three ACT in use in Angola are still highly 
effective against falciparum malaria, while there is some 
variation between the efficacies of the partner drugs 
by site. Although the three sentinel sites are dispersed 
throughout the country (Fig.  1), the efficacy results are 
not necessarily generalizable to the entire country.
No K13 mutations were detected in any of the treat-
ment failures. While there is no guarantee that arte-
misinin resistance in sub-Saharan Africa will necessarily 
be mediated by K13 mutations [24], the absence of K13 
mutations, together with high clearance rates in all arms, 
is strong evidence of a circulating parasite population 
highly susceptible to artemisinin derivatives in the senti-
nel sites. Most of the ETFs occurred in children becom-
ing severely anaemic (haemoglobin ≤5 g/dL) in the first 
two days following treatment. The occurrence of this 
in study participants with already low haemoglobin at 
enrolment might argue for changing the haemoglobin 
criteria at enrolment. Currently, the standard WHO 
in  vivo therapeutic efficacy monitoring protocol rec-
ommends a cut-off for haemoglobin of 5  g/dL, but the 
results here argue for adoption of more stringent criteria 
for future therapeutic efficacy monitoring, for example 
haemoglobin >8 g/dL at enrolment.
Although the ASAQ arm in Lunda Sul did not meet 
its target sample size, the high efficacy of both DP and 
ASAQ in Lunda Sul, the absence of K13 mutants, and 
high clearance rates provide no evidence that a focus of 
artemisinin resistance has been established in Lunda Sul.
Table 1 Number of  participants screened, enrolled, and  finishing follow-up and  characteristics at  baseline as  part 
of therapeutic efficacy monitoring in Angola, 2015
ASAQ artesunate–amodiaquine, AL artemether–lumefantrine, DP dihydroartemisinin–piperaquine
a 28-day follow-up
b 42-day follow-up
Benguela Zaire Lunda Sul
ASAQa ALa ALa DPb DPb ASAQa
Screened, n 445 443 150 223 318 225
 Enrolled, n 101 101 104 102 100 78
 Lost to follow up, 
n (%)
20 (20) 11 (11) 7 (7) 12 (12) 14 (14) 9 (12)
 Excluded, n (%) 8 (8) 5 (5) 4 (4) 6 (6) 10 (10) 13 (17)
 Reached study 
endpoint, n (%)
73 (72) 85 (84) 93 (89) 84 (82) 76 (76) 56 (72)
Participant characteristics at baseline
 Median age, years 
(range)
5.0 (0.7–12) 6.4 (1–12) 3.0 (0.6–5) 2.8 (0.6–5) 2.8 (0.5–5) 3.2 (0.5–5)
 Median weight, kg 
(range)
16 (6–37) 18 (8–42) 13 (7–19) 13 (6–19) 12 (6–21) 12 (7–18)
 Percent female 40% 40% 51% 53% 42% 58%
 Median day 0 
parasitemia, para-
sites/µL (range)
29,487 (1051–
99,507)
20,151 (1003–
92,733)
47,766 (2034–
195,529)
48,049 (2003–
187,777)
7266 (2000–180,903) 16,071 (2000–
161,333)
 Median day 0 
hemoglobin,  
g/dL (range)
10.3 (5.2–13.3) 10.2 (5.4–13.5) 10.2 (5.7–13.6) 10.0 (6–13.3) 9.4 (5.1–13.5) 9.2 (5.5–13.6)
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In general, all three of the partner drugs to the arte-
misinin derivatives were efficacious in sufficiently sup-
pressing the initial malaria infection. No recrudescences 
were observed in either the Benguela or the Lunda Sul 
ASAQ arm. A total of 15 LTFs were observed in the DP 
arms, with all of these occurring in the Zaire arm. The 
42-day uncorrected efficacy of DP in Zaire was estimated 
to be 82.5%, which is lower than expected, as 42-day 
uncorrected efficacies of DP are usually reported to 
be closer to 90% [25], a result possibly explained by an 
unusually high transmission intensity in the Zaire site. 
Eleven (73%) of the LTFs in the Zaire DP arm were past 
28  days of follow-up. All of these were re-infections, as 
the only recrudescence occurred at day 28. As a result, 
Table 2 Treatment outcomes for  participants finishing follow-up as  part of  therapeutic efficacy monitoring in  Angola, 
2015
ASAQ artesunate–amodiaquine, AL artemether–lumefantrine, DP dihydroartemisinin–piperaquine
a 28-day follow-up
b 42-day follow-up
n (%)
Benguela Zaire Lunda Sul
ASAQa ALa ALa DPb DPb ASAQa
n = 73 n = 85 n = 93 n = 84 n = 76 n = 56
Treatment failure 7 (10) 9 (11) 23 (25) 15 (18) 0 0
 Early treatment failure 0 1 (1) 3 (3) 0 0 0
 Late treatment failure 7 (10) 8 (9) 20 (22) 15 (18) 0 0
 Recrudescence 0 1 (1) 8 (9) 1 (1) 0 0
  Day 7 0 0 0 0 0 0
  Day 14 0 0 2 (2) 0 0 0
  Day 21 0 0 6 (6) 0 0 0
  Day 28 0 1 (1) 0 1 (1) 0 0
  Day 35 – – – 0 0 –
  Day 42 – – – 0 0 –
 Reinfection 7 (10) 7 (8) 12 (13) 14 (17) 0 0
  Day 7 0 0 0 0 0 0
  Day 14 0 2 (2) 1 (1) 0 0 0
  Day 21 1 (1) 1 (1) 6 (6) 0 0 0
  Day 28 6 (8) 1 (1) 5 (5) 3 (4) 0 0
  Day 35 – – – 5 (6) 0 –
  Day 42 – – – 6 (7) 0 –
Adequate clinical and parasitological response 66 (90) 76 (89) 70 (75) 69 (82) 76 (100) 56 (100)
Table 3 Proportion of  slides negative for  asexual malaria parasites on  day 2 and  3 following  anti-malarial treatment, 
therapeutic efficacy monitoring in Angola, 2015
ASAQ artesunate–amodiaquine, AL artemether–lumefantrine, DP dihydroartemisinin–piperaquine
Proportion slides negative (95% confidence intervals)
Benguela Zaire Lunda Sul
ASAQ AL AL DP DP ASAQ
Day 2 99 (93–100) 98 (92–100) 95 (87–98) 94 (87–97) 100 (93–100) 100 (90–100)
Day 3 100 (95–100) 100 (95–100) 99 (93–100) 99 (94–100) 100 (92–100) 100 (89–100)
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the corrected 28- and 42-day efficacies for DP were vir-
tually identical and approaching 100% in both Zaire and 
Lunda Sul.
The AL arms recorded a total of 38 LTFs, despite only 
a 28-day follow-up duration, resulting in 28-day uncor-
rected efficacies below 90% in both Benguela and Zaire. 
This was likely partly due to lumefantrine having a signif-
icantly shorter half-life than piperaquine [26]. The longer 
prophylactic effect of DP, confirmed here, should perhaps 
be factored in policy decisions in Angola, as recent mod-
elling work has postulated a reduction in malaria inci-
dence in high transmission areas in Africa if DP were to 
be used in place of AL [27].
Amongst the 38 LTFs observed in the AL arms, nine 
were classified as recrudescent infections. While only 
one of the LTFs in Benguela was a recrudescence of the 
original infection, there were eight recrudescences noted 
in the AL arm in Zaire. Combined with three ETFs, this 
resulted in a corrected efficacy, using the Kaplan–Meier 
estimator, of 88.1% in Zaire, close to the 89.6% estimate 
reported in 2013 [17]. It is also close to the efficacy esti-
mate of 91.3% in 2011–2013 in Luanda. However, com-
parison of these efficacies is complicated by different 
upper age limits of the study participants: up to five years 
in Zaire in 2015, up to nine years in Zaire in 2013, and all 
ages in Luanda in 2011–2013. Nevertheless, the results 
are a continuation of the trend of AL efficacy in Zaire 
below the 90% lower limit of efficacy recommended for 
ACT, and are cause for concern.
The preponderance of pfmdr1 NYD and NFD haplo-
types in AL recrudescent and incident infections during 
follow-up closely matches data from the 2013 therapeutic 
efficacy monitoring in Zaire and Uíge Provinces, where 
91% of AL treatment failures had NYD or NFD haplo-
types on day of failure. This is consistent with evidence 
that NYD and NFD haplotypes are associated with 
decreased susceptibility to lumefantrine and are under 
selection following AL treatment [22, 28, 29]. There was 
no evidence of selection of K13 mutants over the course 
of treatment, as all day-0 and day-of-failure isolates had 
wild type K13 genotypes.
The fact that lumefantrine drug levels were not meas-
ured and that the evening AL doses were not directly 
observed precludes the exclusion of underdosing or mal-
absorption as explanations for the decreased efficacy of 
AL in Zaire Province. Future therapeutic efficacy moni-
toring should incorporate direct observation of all doses 
of AL, including strict adherence to food intake during 
administration of AL, and measurement of day 7 lume-
fantrine levels to definitively rule out the alternative 
hypothesis of underdosing or malabsorption.
The sequential, non-randomized enrolment of study 
participants meant that participants in the different arms 
were exposed to different risk of re-infection as the fol-
low-up period in the second arm in each province took 
place later in the peak transmission season. As a result, 
direct comparison of drug efficacies is difficult across 
study arms.
Table 4 Efficacy of first-line anti-malarials in three therapeutic efficacy monitoring sites in Angola, 2015
Per-protocol efficacy defined as proportion adequate clinical and parasitological response (ACPR), Kaplan–Meier estimate calculated from estimate of survival 
function
ASAQ artesunate–amodiaquine, AL artemether–lumefantrine, DP dihydroartemisinin–piperaquine
a 28-day follow up
b 42-day follow up
Efficacy (95% confidence intervals)
Benguela Zaire Lunda Sul
ASAQa ALa ALa DPb DPb ASAQa
Uncorrected
 Per-protocol Day 28 90.4 (81–96) 89.4 (80–95) 75.3 (65–83) 95.6 (88–99) 100 (94–100) 100 (92–100)
 Per-protocol Day 42 – – – 81.9 (72–89) 100 (94–100) –
 Kaplan–Meier estimate Day 28 90.3 (84–97) 89.6 (83–96) 76.0 (68–85) 95.5 (91–100) 100 100
 Kaplan–Meier estimate Day 42 – – – 82.5 (75–91) 100 –
PCR-corrected
 Per-protocol Day 28 99.9 (95–100) 96.1 (89–99) 86.5 (77–92) 98.8 (94–99) 100 (96–100) 100 (94–100)
 Per-protocol Day 42 – – – 98.5 (92–99) 100 (96–100) –
 Kaplan–Meier estimate Day 28 99.9 (95–100) 96.3 (91–100) 88.1 (81–95) 98.8 (96–100) 100 100
 Kaplan–Meier estimate Day 42 – – – 98.8 (96–100) 100 –
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Conclusion
Overall, the 2015 round of efficacy monitoring in Angola 
confirms the continued sensitivity of P. falciparum para-
sites to artemisinin derivatives, points to high efficacy of 
amodiaquine and piperaquine as partner drugs, and reaf-
firms a low efficacy of lumefantrine in Zaire Province in 
northern Angola. Further routine efficacy monitoring, 
including direct observation of all doses and blood drug 
level measurement, is recommended.
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